Mohammed Haneefa Nizamudeen
- Vertex Pharmaceuticals (VRTX) said that data from a phase 2b trial found that the experimental drug inaxaplin led to a significant decline in proteinuria in individuals with APOL1-mediated kidney disease (AMKD).
- Results from the AMPLIFIED study showed that in one